707 related articles for article (PubMed ID: 10523895)
1. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
2. Current treatment of BPH.
Roylance P; Gibelin B; Espié J
Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
[TBL] [Abstract][Full Text] [Related]
3. Treatment and pharmacologic management of BPH in the context of common comorbidities.
O'Leary MP
Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
[TBL] [Abstract][Full Text] [Related]
4. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
Rosario DJ; Phillips JT; Chapple CR
J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
[TBL] [Abstract][Full Text] [Related]
5. [Current drug therapy of benign prostatic hyperplasia].
Schmidbauer CP; Madersbacher S
Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
[TBL] [Abstract][Full Text] [Related]
6. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
7. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
[TBL] [Abstract][Full Text] [Related]
9. Medical management of benign prostatic hypertrophy.
Nix JW; Carson CC
Can J Urol; 2007 Dec; 14 Suppl 1():53-7. PubMed ID: 18163946
[TBL] [Abstract][Full Text] [Related]
10. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
Jolliet P; Bourin M
Therapie; 1998; 53(1):61-6. PubMed ID: 9773101
[TBL] [Abstract][Full Text] [Related]
11. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
12. BPH: costs and treatment outcomes.
Nickel JC
Am J Manag Care; 2006 Apr; 12(5 Suppl):S141-8. PubMed ID: 16613528
[TBL] [Abstract][Full Text] [Related]
13. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
14. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation.
Grise P; Plante M; Palmer J; Martinez-Sagarra J; Hernandez C; Schettini M; Gonzalez-Martin M; Castiñeiras J; Ballanger P; Teillac P; Rolo F; Baena V; Erdmann J; Mirone V
Eur Urol; 2004 Oct; 46(4):496-501; discussion 501-2. PubMed ID: 15363567
[TBL] [Abstract][Full Text] [Related]
16. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
17. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
Kaplan SA; Olsson CA; Te AE
J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
[TBL] [Abstract][Full Text] [Related]
18. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of benign prostatic hyperplasia.
Edwards JL
Am Fam Physician; 2008 May; 77(10):1403-10. PubMed ID: 18533373
[TBL] [Abstract][Full Text] [Related]
20. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
